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Collecting duct renal carcinoma (CDC) or Bellini 
cancer is a rare subtype of renal cell carcinoma (RCC), 
initiated from distal part of the collecting ducts. At the 
time of diagnosis, about 50% of the patients are found 
to have metastases and a poor outcome. The response to 
chemotherapy in CDC patients is modest and overall 
survival is less than 1 year. Several regimens that 
include methotrexate, vinblastine, doxorubicin, 
cisplatin, gemcitabine or paclitaxel have been used to 
treat CDC patients [1]. Clinical trials with targeted 
therapies also did not result in a favorable outcome 
except for selected cases. These findings suggest that 
there is lack of knowledge on the biology and molecular 
architecture of these tumors. To understand the 
mechanisms responsible for drug resistance and to 
develop novel therapies for this lethal disease we have 
recently performed whole exome (WES) and 
transcriptome sequencing (RNAseq) on 7 CDC 
samples, and we have confirmed specific gene 
alterations by FISH and immunohistochemistry analysis 
in a larger cohort (n=16) of cases [2]. We have found 
frequent loss of CDKN2A (62.5%, 10 out of 16) and 
overexpression of several SLC family transporters 
including xCT, Cystine transporter (SLC7A11 gene; 
80% 12 out of 15), PROT, Proline transporter (SLC6A7 
gene; 100% 5 out of 5) and GLAST, glutamate and 
aspartate transporter (SLC1A3 gene; 80% 4 out of 5) in 
CDC cases [2]. This is the first report to show 
overexpression of xCT, a cisplatin resistance associated 
gene [3], in CDC and to shed some light on the 
molecular mechanisms responsible for drug resistance. 
PROT and GLAST involved in transport of Proline and 
Glutamate and Aspartate have also been showed to be 
markers associated with drug resistance [4,5]. Our 
findings suggest that targeting these pathways in CDC 
may be beneficial and achievable. There are FDA 
approved drugs that target xCT and PROT, respectively, 
and could be “repurposed” while waiting to develop 
more selected agents. For example, sulfasalazine is an 
anti-inflammatory drug used for colitis and arthritis and 
targets xCT [3], while benzatropine is an anticholinergic 
agent used to reduce side effects of antipsychotic 
treatments and targets PROT [6].   
In order to better understand the biology of CDC, 
further genomic and proteomic studies are needed. 
Recently, two other groups have published  the genomic  
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profiling of CDC tumors. i) A comprehensive genomic 
profiling study in 17 CDC patients reporting a common 
alteration in NF2 (29% 5 out of 17) and suggesting a 
potential therapeutic role for mTOR inhibitors in CDC 
[7]. ii) A unique transcriptome sequencing analysis 
performed on CDC (n=17) comparing with Upper Track 
Urothelial Carcinomas (UTUC) and other kidney 
carcinomas [8]. The results from the latter study are 
quite interesting. The authors discovered that the origin 
of the CDC is from distal convoluted tubules and 
possess distinct transcriptome signature among of 
kidney cancer subtypes. Further, they also showed a 
metabolic shift in CDC with impaired tricarboxylic acid 
cycle, pyruvate metabolism and oxidoreductases activi- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genomic profiling of collecting duct renal carcinoma   
 
Sreenivasulu Chintala and Roberto Pili 
  www.aging-us.com           AGING 2016, Vol. 8, No. 10
Figure  1.  p‐mTOR  is  overexpressed  in  collecting  duct
carcinoma  tumors.    Immunohistochemical  detection  of  p‐
mTOR  in  FEPE  sections. Representative  photomicrographs  of
matched normal kidney  (upper panel) and CDC  tumor  (lower
panel). 
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ty along with the immunogenic response and increased 
infiltrating lymphocytes especially in the metastatic 
cases. The authors concluded that CDC exhibits a 
‘pathognomonic transcriptomic’ signature with the 
alteration of immunogenic and metabolic pathways 
indicating that targeting these pathways might be a 
therapeutic option for CDC patients. Our findings of 
CDKN2A deletion and overexpression of several 
oncogenic genes and drug resistance SLC family 
transporters also suggest that metabolic reprograming is 
a critical alteration in CDC and targeting these 
pathways might lead to improve the clinical outcome of 
patients. Our unpublished data (Figure 1) revealed the 
overexpression of p-mTOR, a nutritional sensing 
pathway in 50% (3 out of 6) of CDC cases compared to 
match normal kidney, again supporting the hypothesis 
that CDC is a metabolic disease.    
In conclusions due to the rarity of the CDC patients, 
clinicians and researcher working on this disease should 
get together to pool the available resources and further 
investigate the molecular alterations by using the 
currently available advanced Omics technologies. A 
consensus agreement on the potential treatment options 
will be beneficial for all the patients affected by this 
rare but dreadful disease.  
. 
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